News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders
A study published in Cancer Cell has identified a novel population of PTGER3-positive cancer-associated fibroblasts (CAFs) that emerge specifically in bladder cancer patients who respond to neoadjuvant chemotherapy. These chemotherapy-induced fibroblasts undergo lipid oxidation reprogramming and actively enhance CD8+ T cell function, thereby remodeling the tumor microenvironment and restraining tu…
Hallmarks of cancer—Then and now, and beyond
In a landmark review published in Cell, Douglas Hanahan revisits and expands the influential Hallmarks of Cancer framework, which has shaped oncology research for a quarter-century. The updated synthesis integrates aberrant cellular capabilities, enabling traits, tumor microenvironment dynamics, and systemic host interactions into a multidimensional model of tumorigenesis. Hanahan proposes that me…
Microbiota and immune-related adverse events in cancer immunotherapy
A new Progress article published in Nature Reviews Cancer by Schneider et al. examines the growing body of evidence linking the gut microbiome to the development and progression of immune-related adverse events (irAEs) during cancer immunotherapy. The review synthesizes both clinical and preclinical data demonstrating that specific microbial compositions can influence the risk of complications suc…
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy
A study published in Nature Cancer by Li et al. presents a comprehensive multi-omics analysis of nasopharyngeal carcinoma (NPC), a malignancy most prevalent in Southeast Asia and southern China. The researchers identified three distinct molecular subtypes of NPC, each characterized by unique immune microenvironment profiles and differing responses to induction chemotherapy. These findings could pa…
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177 Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
A substudy of the randomized phase 2 ENZA-p trial, published in Nature Cancer, evaluated the frequency, magnitude, and clinical significance of early prostate-specific membrane antigen (PSMA) upregulation in patients with poor-risk metastatic castration-resistant prostate cancer treated with enzalutamide alone or combined with the radioligand therapy 177Lu-PSMA-617. The findings by Emmett and coll…
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
A randomized, placebo-controlled trial (Alliance A222001) published in the Journal of Clinical Oncology evaluated oxybutynin, an anticholinergic agent, for the management of hot flashes in prostate cancer patients undergoing androgen-deprivation therapy (ADT). Hot flashes are among the most common and distressing side effects of ADT, significantly affecting quality of life for a large proportion o…
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Results from the randomized phase II NIPINEC trial (GCO-001), published in the Journal of Clinical Oncology, evaluated the efficacy of nivolumab alone versus nivolumab combined with ipilimumab in patients with previously treated advanced neuroendocrine carcinoma (NEC). Neuroendocrine carcinomas are rare, aggressive malignancies with very limited treatment options after progression on first-line pl…
Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening
A study published in the Journal of Clinical Oncology examined how pre-diagnosis financial hardship influences the likelihood of patients presenting with late-stage cancer and whether screening programs can mitigate this effect. The researchers found that individuals experiencing significant financial difficulties before a cancer diagnosis were more likely to be diagnosed at advanced stages, when …
The Oncology Care Model and Payments, Utilization, and Quality
A study published in JAMA evaluated the Medicare Oncology Care Model (OCM), a major alternative payment program designed to improve the value of cancer care delivered to Medicare beneficiaries. Using a difference-in-differences regression design, researchers compared Medicare spending, healthcare utilization, and quality-of-care metrics between oncology practices that voluntarily participated in t…
Many Older Adults With Cancer Prioritize Quality of Life Over Survival
A study published in JAMA Oncology found that the majority of older adults with advanced cancer prefer to prioritize preserving their quality of life over treatments aimed at prolonging survival. Despite this strong patient preference, the research suggests that these wishes are frequently not adequately incorporated into clinical decision-making and treatment planning. The findings underscore a c…